tbuckley/cabot-search huggingface dataset:
Intensive Care
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
WHAT AMOUNT OF VISUAL DEFECT SHOULD DISQUALIFY IN RAILROAD SERVICE?
Authors: FRANK ALLPORT
Journal: JAMA (1902)

At the last meeting of the Ophthalmological Section of the American Medical Association, I presented a report on the above subject, accompanied by tabulated statistics. In order to accumulate material for this report, I sent letters of inquiry and a question blank to every railroad in the United States, Canada and Mexico, operating over one hundred miles of road; 244 railroads were thus addressed, covering 205,638 miles of road. I received replies from 64 roads operating 90,950 miles of road. This left a large amount of mileage unaccounted for, and in order to endeavor to supply this deficiency, during the past year I communicated with all those roads failing to reply to my first communication. I received replies from 48 roads, making a total of 112 roads that have replied to my letters of inquiry. The roads thus heard from during the past year cover a mileage of 56,888 miles,
Handbuch der inneren Sekretion: Eine umfassende Darstellung der Anatomie, Physiologie und Pathologie der endokrinen Drüsen.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Sookmyung Women’s University JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account
Are Human Studies Possible? Some Thoughts on the Mutation Component and Population Monitoring
Authors: Carter Denniston
Journal: Environmental Health Perspectives (1983)

The concept of the mutation component of a genetic trait is discussed and its relation to heritability investigated. It is found that for qualitative traits held in the population by opposing directional selection and mutation, the mutation component equals the broad sense heritability. The mutational component of a quantitative trait with an intermediate optimum is found generally to be between half and one times the (narrow sense) heritability of the character. Although more work on this matter is required, the finding of a relationship between mutation component and heritability should allow us to make better predictions regarding the likely impact of an increased mutation rate on the human population. Some statistical problems relevant to the detection of an increased mutation rate are also discussed.
Book Review Cancer of the Face and Mouth: Diagnosis, treatment, surgical repair . By Vilray P. Blair, M.D., Sherwood Moore, M.D., and Louis T. Byars, M.D. 4°, cloth, 599 pp., with 260 illustrations and 64 plates. St. Louis: The C. V. Mosby Company, 1941. $10.00.
Journal: New England Journal of Medicine (1942)
Canadian J Biochemistry &amp;amp; Physiology, Ottawa
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pulmonary fibrosis masking polymyositis. Remission with corticosteroid therapy
Authors: D. R. Webb
Journal: JAMA (1972)

A case of polymyositis with pulmonary fibrosis was unusual in that a striking remission occurred after high-dosage therapy with corticosteroids was instituted. This remission has persisted now for some 20 months. The presence of muscle disease in this patient and in several patients previously reported was masked by the more impressive symptoms of pulmonary disease. A search for occult muscle disease in patients with pulmonary fibrosis is recommended. The presence of inflammatory muscle disease in patients with pulmonary fibrosis suggests high-dosage therapy with corticosteroid (80 to 100 mg prednisone daily) may be required for therapeutic response.
No 'extra' cancer deaths noted from atomic studies
Authors: Charles Marwick
Journal: JAMA (1985)

A study—by the National Research Council of the National Academy of Sciences, Washington, DC—has been unable to find any new evidence of increased deaths from cancer related to radiation exposure in some of the early atomic bomb tests. The council investigators studied more than 46,000 of the approximately 49,000 servicemen who were exposed to radiation while participating in at least one of five announced atmospheric nuclear tests of various atomic weapons between 1951 and 1958. (In all, there were 18 announced US tests of this type between 1946 and 1962.) The study did confirm a previously reported number of excess deaths from leukemia—ten, as compared with the 3.97 deaths expected—among a group of 3,741 participants in one test (<i>JAMA</i>1983;250:620-624). The men in this group had participated in a test called "Smoky" of the Nevada test site series in 1957. The National Research Council investigators also uncovered evidence of what
I Remember <i>It</i> Well
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conformational Properties of Molecules by ab Initio Quantum Mechanical Energy Minimization
Authors: L. Pedersen
Journal: Environmental Health Perspectives (1985)

The recent literature on the determination of minimum energy conformations by ab initio quantum mechanical techniques is reviewed. The availability of computer-coded analytical first and second derivatives of the Hartree-Fock energy makes possible calculations that will be of significant assistance in structure determination of molecules. A short review of recent progress in empirical energy minimization and molecular dynamics is provided.
Revista Mexicana de Urologia, Mexico
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Robotically assisted cardiac surgery: The Dresden experience Romuald Cichon, Utz Kappert, Jens Schneider, Ina Schade, Vassilios Gulielmos, Sems Malte Tugtekin, Klaus Matschke, Stephan Schueler. Cardiovascular Institute, University of Dresden, Dresden, Germany
Journal: Journal of the American College of Cardiology (2001)
Abstract 4765: MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer
Authors: Dan Yan, Justus Huelse, Rebecca Parker, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Deborah DeRyckere, Douglas Graham
Journal: Cancer Research (2019)

Abstract Non-small cell lung cancer (NSCLC) remains a global problem causing more deaths in both men and women than any other cancer worldwide with an urgent need for more efficacious treatments. During the last decade the therapeutic landscape for NSCLC has been profoundly changed with the discovery of activating mutations in Epidermal Growth Factor Receptor (EGFR) (EGFRMT). Osimertinib, a 3rd generation EGFR TKI, was recently FDA-approved as a front-line agent for newly diagnosed EGFRMT NSCLCs due to its superior efficacy relative to earlier-generation EGFR TKIs in the international FLAURA trial. However, unmet clinical needs have arisen in conjunction with osimertinib use, including understanding mechanisms of osimertinib resistance and developing novel approaches to prevent or reverse resistance and/or enhance osimertinib efficacy in responsive patients. Our group previously identified MERTK receptor tyrosine kinase as a potential therapeutic target in NSCLC and developed MRX-2843, a novel small molecule inhibitor with dual MERTK and FLT3 activity, which is currently in Phase I clinical trials. Here, we report upregulation of MERTK and its ligand PROS1 in xenograft tumors derived from the EGFRMT H4006 NSCLC cell line and treated with osimertinib relative to vehicle-treated tumors. MERTK expression was also increased in osimertinib-resistant derivatives of the H4006 and H4011 cell lines generated by culture in escalating doses of osimertinib. However, overexpression of exogenous MERTK in H4006 cells was not sufficient to confer osimertinib resistance. In contrast, stimulation with TAM kinase ligands GAS6 or PROS1 protected H4006 cells from osimertinib treatment, as indicated by restoration of AKT, ERK, and ribosomal S6 phosphorylation in the presence of osimertinib. Together these data implicate MERTK as a mediator of resistance to osimertinib. Indeed, combined treatment with osimertinib and MRX-2843 effectively blocked PI3K-AKT and MAPK-ERK signaling and mediated synergistic inhibition of colony formation in osimertinib-resistant H4006 cells. Thus, MERTK inhibition may be an effective therapeutic strategy to re-sensitize osimertinib-resistant NSCLCs to EGFR TKI treatment. Citation Format: Dan Yan, Justus Huelse, Rebecca Parker, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Deborah DeRyckere, Douglas Graham. MERTK is a potential therapeutic target in osimertinib-resistant non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4765.
Carandiru
Authors: Waqar Rashid
Journal: BMJ (2004)

Directed by Hector Babenco At selected UK cinemas Rating:![Graphic][1]</img>![Graphic][2]</img> In a way, Carandiru , the latest film from Brazilian director Hector Babenco—who made the hit 1985 film Kiss of the Spider Woman —offers a medical perspective of a horrific event. It is based on actual events at a massively overcrowded detention centre in Brazil in 1992, when police stormed the building following a riot and 111 inmates were killed. It is told through the eyes of the prison's doctor (played by Luiz Carlos Vasconcelos) as a neutral authority figure. [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif
Death, Dying, and the Biological Revolution: Our Last Quest for Responsibility
Authors: L. D. Hankoff
Journal: JAMA (1989)

This is a revision of Veatch's earlier work of the same title. In the 13 years since his first version, the field of medical ethics has become a growth industry, although by now most of the issues are being confronted. The cases presented here are the same ones, by and large, as in the earlier volume and have become standard reference points. Little has been added since the first edition. For example, the Karen Quinlan case, referred to 4 times in his 1976 book, is discussed 10 times in the present volume. The volume provides a thorough review of the ethical issues pertaining to the definition of death, the application of extraordinary care, informing patients of a life-threatening illness, the harvesting of organs for transplant, and, finally, Veatch's pet idea The Pursuit of Immortality. It is in relation to the latter area that Veatch informs us that "the time has
Théorie des vitamines et ses applications. Essais de vitaminologie.
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
Authors: R. C. Petersen
Journal: JAMA (1995)

<h3>Objective.</h3> —The outcome of patients with mild cognitive impairment is not known, yet these patients present a difficult dilemma for the clinician. This study was designed to characterize the outcome of a group of patients with mild cognitive impairment and to determine whether the presence of the ε4 allele on the apolipoprotein E gene (<i>APOE</i>) is a predictor of that outcome. <h3>Design.</h3> —A prospective, longitudinal inception cohort. <h3>Setting.</h3> —General community clinic. <h3>Participants.</h3> —A consecutive sample of 66 patients who met criteria for a diagnosis of a mild cognitive impairment and who had at least one clinical reevaluation was identified from the Mayo Clinic Alzheimer's Disease Center/Alzheimer's Disease Patient Registry. <h3>Interventions.</h3> —We evaluated patients initially and at 12- to 18-month intervals up to 54 months using standard neurological and neuropsychological measures such as the Mini-Mental State Examination, the Dementia Rating Scale, the Wechsler Adult Intelligence Scale—Revised, the Wechsler Memory Scale—Revised, and the Free and Cued Selective Reminding Test. The<i>APOE</i>status of study patients was determined. <h3>Main Outcome Measure.</h3> —The development of dementia as determined by the<i>Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition</i>and the National Institute of Neurological and Communicative Disorders and Stroke/ Alzheimer's Disease and Related Disorders Association criteria. <h3>Results.</h3> —Sixty-six individuals had been reevaluated once (mean of 18 months), 36 individuals twice (mean of 36 months), and 22 individuals on three occasions (mean of 54 months), with conversion rates to dementia at these intervals of 24%, 44%, and 55%, respectively. A multivariate Cox regression model demonstrated that possession of an<i>APOE</i>ε4 allele was the strongest predictor of clinical outcome. <h3>Conclusions.</h3> —These data suggest the following: (1) patients with mild cognitive impairment can be clinically defined, (2) many members of this group progress to Alzheimer's disease, and (3)<i>APOE</i>ε4 allele status appears to be a strong predictor of clinical progression. (<i>JAMA</i>. 1995;273:1274-1278)
Digitalis Intoxication—The 'Insidious Twin of Treatment'
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quality Measures
Authors: Tracy Hampton
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Richard Havel, Howard Eder, and the evolution of lipoprotein analysis
Authors: S. M. Grundy
Journal: Journal of Clinical Investigation (2004)

In 1956, the JCI published a paper by Richard Havel, Howard Eder, and Joseph Bragdon on a method using an ultracentrifuge to physically separate plasma lipoproteins and chemical methods to analyze their lipid constituents. This paper has been much cited (7081 times as of this writing) in part because it represents a solid method that, with various modifications, has been applicable for the study of lipoproteins for almost half a century.
Reply to Emre Karabay and İlker Tınay’s Letter to the Editor re: Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066
Authors: Marc-Oliver Grimm, Christien Caris, Wim P.J. Witjes
Journal: European Urology (2020)
Sixth Summer Program In Methods of Immunologic Research and Diagnosis
Journal: JNCI Journal of the National Cancer Institute (1978)

Sixth Summer Program In Methods of Immunologic Research and Diagnosis Get access JNCI: Journal of the National Cancer Institute, Volume 61, Issue 6, December 1978, Page 1547, https://doi.org/10.1093/jnci/61.6.1547-c Published: 01 December 1978